Imperial College London
Alternate

DrSanjayPopat

Faculty of Medicine, National Heart & Lung Institute

Reader in Cancer Medicine
 
 
 
//

Contact

 

+44 (0)20 7808 2132s.popat Website

 
 
//

Location

 

Royal Marsden HospitalThe Royal Marsden Hospital

//

Summary

 

Publications

Citation

BibTex format

@article{Camidge:2021:10.1016/j.jtho.2021.07.035,
author = {Camidge, DR and Kim, HR and Ahn, M-J and Yang, JCH and Han, J-Y and Hochmair, MJ and Lee, KH and Delmonte, A and Campelo, MRG and Kim, D-W and Griesinger, F and Felip, E and Califano, R and Spira, AI and Gettinger, SN and Tiseo, M and Lin, HM and Liu, Y and Vranceanu, F and Niu, H and Zhang, P and Popat, S},
doi = {10.1016/j.jtho.2021.07.035},
journal = {JOURNAL OF THORACIC ONCOLOGY},
pages = {2091--2108},
title = {Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial},
url = {http://dx.doi.org/10.1016/j.jtho.2021.07.035},
volume = {16},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AU  - Camidge,DR
AU  - Kim,HR
AU  - Ahn,M-J
AU  - Yang,JCH
AU  - Han,J-Y
AU  - Hochmair,MJ
AU  - Lee,KH
AU  - Delmonte,A
AU  - Campelo,MRG
AU  - Kim,D-W
AU  - Griesinger,F
AU  - Felip,E
AU  - Califano,R
AU  - Spira,AI
AU  - Gettinger,SN
AU  - Tiseo,M
AU  - Lin,HM
AU  - Liu,Y
AU  - Vranceanu,F
AU  - Niu,H
AU  - Zhang,P
AU  - Popat,S
DO  - 10.1016/j.jtho.2021.07.035
EP  - 2108
PY  - 2021///
SN  - 1556-0864
SP  - 2091
TI  - Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
T2  - JOURNAL OF THORACIC ONCOLOGY
UR  - http://dx.doi.org/10.1016/j.jtho.2021.07.035
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000721176100017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL  - 16
ER  -
Download